Linda C. Meade-Tollin

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DragonflySixtyseven (talk | contribs) at 00:39, 13 July 2020 (Marquis in the early 20th century was notability. Marquis today is not.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Linda Celida Meade-Tollin (1944-) biochemist.

Background

Meade-Tollin was born in West Virginia, studying chemistry at West Virginia State College in 1964.[citation needed] Meade-Tollin worked at Harlem and Bellevue Hospitals before entering a chemistry PhD program at the City University of New York in 1972, transferring to biochemistry the following year, writing her doctoral thesis on gene expression in E. coli.

Meade-Tollin's first faculty appointment was at the College at Old Westbury, and acted as a visiting assistant professor at Rockefeller University, working on sickle cell anemia. Meade-Tollin received a National Institutes of Health postdoctoral award at the University of Arizona, where she was the only African-American woman to head a biomedical research laboratory at the University, and her research focused on DNA damage, angiogenesis, and cancer invasion and metastasis[1]. Meade-Tollin developed a new bioassay for angiogenesis in human microvascular endothelial cells, which was used to identify inhibitors and enhancers from desert fungi, and she spent a year as Faculty Development Fellow at Morehouse School of Medicine[2].

Awards

Meade-Tollin received of the Minority Investigator award from the National Cancer Institute in 1987 and 1990, and the Minority Investigator award from the National Heart Lung and Blood Institute in 1994.[citation needed]

References

  1. ^ "Linda C Meade-Tollin". Loop Frontiers.
  2. ^ African American women chemists. Oxford University Press. pp. 74–83. ISBN 9780199742882.